Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20519978 | 1.00 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL20519979 | 1.00 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL20520091 | 0.89 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL30107319 | 0.89 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL21334489 | 0.89 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL20519443 | 0.89 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL21334899 | 0.88 | MAP4K1 (0.79) | MAP4K1 | |
| SCHEMBL21334379 | 0.87 | MAP4K1 (0.83) | MAP4K1 | |
| SCHEMBL21335056 | 0.87 | MAP4K1 (0.83) | MAP4K1 | |
| SCHEMBL20518968 | 0.86 | MAP4K1 (1.00) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | MAP4K1 59/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | MAP4K1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.